Therefore, the appearance of atypical drugs ...

Therefore, the appearance of atypical drugs with different mechanisms of action (to selectively block specific subtypes of dopamine and serotonin retseptrov) type of clozapine, olanzapine, quetiapine and risperidone, have little extrapyramidal side effects and are able to neutralize deficit disorder, is quite encouraging and promising direction (Mosolov SN, 2001). Actively conducting clinical trials of new representatives of atypical antipsychotics. Without causing marked extrapyramidal side effects, atypical antipsychotics have a significantly higher physiological and psychological tolerance, has contributed to apply them as a long-term preventive treatment. In conjunction with rehabilitative interventions, this approach leads to significant improvement in the level sotsialnotrudovoy adaptation of patients and improve their quality of life assessments. Appearance in the near future, long-acting forms of new generation antipsychotics appear to be in even greater extent, help solve problems of long-term therapy, since it would largely solve the problem of insufficient complains of patients with schizophrenia.? Perfect ? antipsychotic, apparently, must possess a wide range of biochemical and clinical antipsychotic action, ie must be both effective in different syndromes options and stages of schizophrenia, affect both plant productivity and on negative symptoms and cognitive impairment, while at the same time, it should not cause significant side effects and lead to the development of the phenomenon of adaptation, ie . should be well tolerated and remain effective for a long time without increasing the dose. With regard to antidepressants, from the standpoint of the clinician, the ongoing efforts of scientists, apparently, should be concentrated on developing more effective, selective and high-speed preparations. Antidepressants in recent years are one of the fastest growing classes of psychotropic drugs. Created a new generation of timoanaleptikov selectively blocking the presynaptic norepinephrine capture (reboksetin, tomoksetin), serotonin (fluoxetine, fluvoxamine, sertraline, paroxetine, citalopram) and dopamine (amineptine, bupropion), which do not cause those or other side effects of tricyclic antidepressants (cholinolytic, adrenolytic , cardiotoxic, etc.). Among MAO inhibitors in clinical practice, there were only reversible inhibitors of monoamine oxidase type A (moclobemide, pirazidol). In clinical terms, it was found that MAO inhibitors over tricyclic antidepressants are effective for social phobias and so-called atypical depression, which are defined as long there is an original trevozhnodepressivnye State, accompanied by somatovegetative and neurosis (mostly obessivnofobicheskimi) disorders. Unlike tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs) (fluoxetine, fluvoxamine, sertraline, paroxetine, citalopram) is more addressed to a wide range of depression neurotic level.